Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)

• Dr. Guillaume Dorothée, Ph.D., is a tenured research director and team head in neuroimmunology at the French National Institute of Health and Medical Research (INSERM) in Paris
• He is one of the world’s leading experts on the role that the immune system and peripheral-central immune crosstalk play in the pathophysiology of AD
• His team was the first to illustrate the beneficial role of Regulatory T cells (Tregs) in AD and the therapeutic effects of low dose Interleukin-2 (low dose IL-2) in modifying AD pathology and restoring cognitive function
• Dr. Dorothée joins an SAB with leading Treg experts including Dr. Shimon Sakaguchi, the discoverer of Tregs, and the chair of Coya’s SAB, Dr. Stanley Appel, who elucidated the role of Tregs in Amyotrophic Lateral Sclerosis (ALS)
• Dr. Dorothée will play an integral role in guiding Coya on its scientific and clinical strategy in AD and other neurodegenerative diseases

 

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Guillaume Dorothée, Ph.D., to Coya’s SAB, joining a roster of scientific luminaries. Dr. Dorothée will provide insight and perspective into Coya’s clinical programs in ALS and AD, and other indications that Coya is evaluating.

Dr. Dorothée’s seminal work has focused on the role of the immune system and peripheral-central immune crosstalk in the pathophysiology of AD and other neurodegenerative diseases, with a particular interest in neuroinflammation and its effects on beta Amyloid, Tau, and other AD pathology. He has pioneered research into understanding how Tregs critically control immune responses to Beta Amyloid (Toly-Ndour et al, J Immunol, 2011), and how enhancing Tregs with low dose IL-2 plays a beneficial role in the pathophysiology of AD-like amyloid pathology while restoring cognitive function (Dansokho et al, Brain, 2016).

“Coya could not be prouder in having Dr. Dorothée join its SAB. The fact that he discovered the therapeutic role of low dose IL-2 in AD dovetails with Coya’s low dose IL-2 asset, COYA 301, and its highly promising proof of concept clinical data showing cognitive improvement and halting of cognitive decline. He continues to publish on the mechanism of how Tregs are working in AD and we look forward to his active participation in guiding our path forward,” stated, Howard H. Berman, Ph.D., CEO of Coya Therapeutics.

Dr. Dorothée commented: “I am glad and honored to join such eminent scientists on the prestigious SAB of Coya Therapeutics. I am fully convinced that innovative Treg-based immunomodulatory approaches, as developed by Coya, are highly promising therapeutic strategies for the treatment of neurodegenerative disorders and other neuroinflammatory conditions. I will be happy to help Coya Therapeutics in this exciting endeavor.”

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s lead therapeutic programs includes Treg-enhancing biologics (COYA 300 Series product candidates) COYA 301 and COYA 302, which are intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. For more information about Coya, please visit www.coyatherapeutics.com

Forward-Looking Statements

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005074/en/

Investor Contact

David Snyder

david@coyatherapeutics.com

Hayden IR

James Carbonara

(646)-755-7412

James@haydenir.com

Media Contact

Jessica Starman

media@coyatherapeutics.com

Source: Coya Therapeutics, Inc.